Integrating clinical metabolomics-based biomarker discovery and clinical pharmacology to enable precision medicine

European Journal of Pharmaceutical Sciences

Volumn 109, Issue , 2017, Pages S15-S21

  Kohler, Isabelle ^a   Hankemeier, Thomas ^a   van der Graaf, Piet H ^a   Knibbe, Catherijne A J ^a   van Hasselt, J G Coen ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Biomarkers; Metabolomics; Pharmacokinetic pharmacodynamic modeling; Pharmacology; Precision medicine

Indexed keywords

BIOLOGICAL MARKER;

CLINICAL PHARMACOLOGY; CLINICAL STUDY; DATA ANALYSIS; DISEASE COURSE; HUMAN; MATHEMATICAL MODEL; METABOLOMICS; MULTIVARIATE ANALYSIS; NONHUMAN; PERSONALIZED MEDICINE; PHARMACODYNAMICS; PHARMACOKINETIC PARAMETERS; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; SAMPLE; SAMPLE SIZE; SAMPLING; STORAGE; STUDY DESIGN; TREATMENT RESPONSE; VALIDATION STUDY; BIOLOGICAL MODEL; DEVICES; DISEASE EXACERBATION; METABOLISM; PROCEDURES;

BIOMARKERS; DISEASE PROGRESSION; HUMANS; METABOLOMICS; MODELS, BIOLOGICAL; PHARMACOLOGY, CLINICAL; PRECISION MEDICINE; PROGNOSIS;

EID: 85019408321     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2017.05.018     Document Type: Review

References (60)

1. Beger, R.D., Dunn, W., Schmidt, M.A., Gross, S.S., Kirwan, J.A., Cascante, M., Brennan, L., Wishart, D.S., Oresic, M., Hankemeier, T., Broadhurst, D.I., Lane, A.N., Suhre, K., Kastenmuller, G., Sumner, S.J., Thiele, I., Fiehn, O., Kaddurah-Daouk, R., Metabolomics enables precision medicine: “A White Paper, Community Perspective”. Metabolomics, 12, 2016, 149.
2. Beisken, S., Eiden, M., Salek, R.M., Getting the right answers: understanding metabolomics challenges. Expert. Rev. Mol. Diagn. 15 (2015), 97–109.
3. Biomarkers Definitions Working Group, Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69 (2001), 89–95.
4. van den Brink, W.J., Wong, Y.C., Gulave, B., van der Graaf, P.H., de Lange, E.C., Revealing the Neuroendocrine Response after Remoxipride Treatment Using Multi-Biomarker Discovery and Quantifying It by PK/PD Modeling. 2016 (AAPS J).
5. Cardoso, F., van't Veer, L.J., Bogaerts, J., Slaets, L., Viale, G., Delaloge, S., Pierga, J.Y., Brain, E., Causeret, S., DeLorenzi, M., Glas, A.M., Golfinopoulos, V., Goulioti, T., Knox, S., Matos, E., Meulemans, B., Neijenhuis, P.A., Nitz, U., Passalacqua, R., Ravdin, P., Rubio, I.T., Saghatchian, M., Smilde, T.J., Sotiriou, C., Stork, L., Straehle, C., Thomas, G., Thompson, A.M., van der Hoeven, J.M., Vuylsteke, P., Bernards, R., Tryfonidis, K., Rutgers, E., Piccart, M., Investigators, M., 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N. Engl. J. Med. 375 (2016), 717–729.
6. Chagoyen, M., Pazos, F., MBRole: enrichment analysis of metabolomic data. Bioinformatics 27 (2011), 730–731.
7. Chan, P.L., Holford, N.H., Drug treatment effects on disease progression. Annu. Rev. Pharmacol. Toxicol. 41 (2001), 625–659.
8. Cleton, A., de Greef, H.J., Edelbroek, P.M., Voskuyl, R.A., Danhof, M., Application of a combined “effect compartment/indirect response model” to the central nervous system effects of tiagabine in the rat. J. Pharmacokinet. Biopharm. 27 (1999), 301–323.
9. Danhof, M., Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models. J. Pharmacokinet. Pharmacodyn. 42 (2015), 447–462.
10. Danhof, M., Systems pharmacology - towards the modeling of network interactions. Eur. J. Pharm. Sci. 94 (2016), 4–14.
11. Danhof, M., Alvan, G., Dahl, S.G., Kuhlmann, J., Paintaud, G., Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers. Pharm. Res. 22 (2005), 1432–1437.
12. Danhof, M., de Jongh, J., De Lange, E.C., Della Pasqua, O., Ploeger, B.A., Voskuyl, R.A., Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu. Rev. Pharmacol. Toxicol. 47 (2007), 357–400.
13. Danhof, M., de Lange, E.C., Della Pasqua, O.E., Ploeger, B.A., Voskuyl, R.A., Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol. Sci. 29 (2008), 186–191.
14. Dayneka, N.L., Garg, V., Jusko, W.J., Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokinet. Biopharm. 21 (1993), 457–478.
15. Dunn, W.B., Broadhurst, D., Begley, P., Zelena, E., Francis-McIntyre, S., Anderson, N., Brown, M., Knowles, J.D., Halsall, A., Haselden, J.N., Nicholls, A.W., Wilson, I.D., Kell, D.B., Goodacre, R., Human Serum Metabolome, C., Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat. Protoc. 6 (2011), 1060–1083.
16. Dunn, W.B., Wilson, I.D., Nicholls, A.W., Broadhurst, D., The importance of experimental design and QC samples in large-scale and MS-driven untargeted metabolomic studies of humans. Bioanalysis 4 (2012), 2249–2264.
17. Emwas, A.H., Luchinat, C., Turano, P., Tenori, L., Roy, R., Salek, R.M., Ryan, D., Merzaban, J.S., Kaddurah-Daouk, R., Zeri, A.C., Nagana Gowda, G.A., Raftery, D., Wang, Y., Brennan, L., Wishart, D.S., Standardizing the experimental conditions for using urine in NMR-based metabolomic studies with a particular focus on diagnostic studies: a review. Metabolomics 11 (2015), 872–894.
18. Fiehn, O., Metabolomics–the link between genotypes and phenotypes. Plant Mol. Biol. 48 (2002), 155–171.
19. Giskeodegard, G.F., Davies, S.K., Revell, V.L., Keun, H., Skene, D.J., Diurnal rhythms in the human urine metabolome during sleep and total sleep deprivation. Sci Rep, 5, 2015, 14843.
20. Goulooze, S.C., Krekels, E.H.J., van Dijk, M., Tibboel, D., Hankemeier, T., Knibbe, C.A.J., Van Hasselt, J.G., 2016. Towards personalized treatment of pain using a quantitative systems pharmacology approach. Eur J Pharm Sci (current issue).
21. van der Graaf, P.H., Benson, N., Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development. Pharm. Res. 28 (2011), 1460–1464.
22. van Hasselt, J.G., van der Graaf, P.H., Towards integrative systems pharmacology models in oncology drug development. Drug Discov. Today Technol. 15 (2015), 1–8.
23. van Hasselt, J.G., Boekhout, A.H., Beijnen, J.H., Schellens, J.H., Huitema, A.D., Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity. Clin. Pharmacol. Ther. 90 (2011), 126–132.
24. van Hasselt, J.G., Gupta, A., Hussein, Z., Beijnen, J.H., Schellens, J.H., Huitema, A.D., Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia. Br. J. Clin. Pharmacol. 76 (2013), 412–424.
25. van Hasselt, J.G., Gupta, A., Hussein, Z., Beijnen, J.H., Schellens, J.H., Huitema, A.D., Disease progression/clinical outcome model for castration-resistant prostate cancer in patients treated with Eribulin. CPT Pharmacometrics Syst Pharmacol 4 (2015), 386–395.
26. Hofman, A., Brusselle, G.G., Darwish Murad, S., van Duijn, C.M., Franco, O.H., Goedegebure, A., Ikram, M.A., Klaver, C.C., Nijsten, T.E., Peeters, R.P., Stricker, B.H., Tiemeier, H.W., Uitterlinden, A.G., Vernooij, M.W., The Rotterdam study: 2016 objectives and design update. Eur. J. Epidemiol. 30 (2015), 661–708.
27. Hyotylainen, T., Oresic, M., Bioanalytical techniques in nontargeted clinical lipidomics. Bioanalysis 8 (2016), 351–364.
28. Innovative Medicines Initative, 2016. Improving the translatability of pharmacodynamic biomarkers in pain pathways of healthy subjects and preclinical species (BIOM), IMI2 - Call 10. https://www.imi.europa.eu/sites/default/files/uploads/documents/Future_Topics/IndicativeTopic_pain.pdf (Accessed 29–11-2016).
29. Jacobs, B.A., Deenen, M.J., Pluim, D., van Hasselt, J.G., Krahenbuhl, M.D., van Geel, R.M., de Vries, N., Rosing, H., Meulendijks, D., Burylo, A.M., Cats, A., Beijnen, J.H., Huitema, A.D., Schellens, J.H., Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers. Br. J. Clin. Pharmacol. 82 (2016), 706–716.
30. Jacqmin, P., Snoeck, E., van Schaick, E.A., Gieschke, R., Pillai, P., Steimer, J.L., Girard, P., Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model. J. Pharmacokinet. Pharmacodyn. 34 (2007), 57–85.
31. Kanani, H., Chrysanthopoulos, P.K., Klapa, M.I., Standardizing GC-MS metabolomics. J. Chromatogr. B. Anal. Technol. Biomed. Life Sci. 871 (2008), 191–201.
32. Knibbe, C.A., Danhof, M., Individualized dosing regimens in children based on population PKPD modelling: are we ready for it?. Int. J. Pharm. 415 (2011), 9–14.
33. Koen, N., Du Preez, I., Loots du, T., Metabolomics and personalized medicine. Adv. Protein Chem. Struct. Biol. 102 (2016), 53–78.
34. Kohler, I., Verhoeven, A., Derks, R.J., Giera, M., Analytical pitfalls and challenges in clinical metabolomics. Bioanalysis 8 (2016), 1509–1532.
35. Lenth, R.V., Some practical guidelines for effective sample size determination. Am. Stat. 55 (2001), 187–193.
36. Lenth, R.V., Statistical power calculations. J. Anim. Sci. 85 (2007), E24–E29.
37. Lin, D., Hollander, Z., Meredith, A., McManus, B.M., 2009. Searching for 'omic' biomarkers. Can J Cardiol 25 Suppl a, 9A-14A.
38. Mandrekar, S.J., Sargent, D.J., Clinical trial designs for predictive biomarker validation: one size does not fit all. J. Biopharm. Stat. 19 (2009), 530–542.
39. Marmot, M., Brunner, E., Cohort profile: the Whitehall II study. Int. J. Epidemiol. 34 (2005), 251–256.
40. Mehta, S.H., Adler, C.H., Advances in biomarker research in Parkinson's disease. Curr Neurol Neurosci Rep, 16, 2016, 7.
41. Mochel, J.P., Fink, M., Peyrou, M., Desevaux, C., Deurinck, M., Giraudel, J.M., Danhof, M., Chronobiology of the renin-angiotensin-aldosterone system in dogs: relation to blood pressure and renal physiology. Chronobiol. Int. 30 (2013), 1144–1159.
42. Nagele, T., Furtauer, L., Nagler, M., Weiszmann, J., Weckwerth, W., A strategy for functional interpretation of Metabolomic time series data in context of metabolic network information. Front. Mol. Biosci., 3, 2016, 6.
43. Pardo, L.M., MacKay, I., Oostra, B., van Duijn, C.M., Aulchenko, Y.S., The effect of genetic drift in a young genetically isolated population. Ann. Hum. Genet. 69 (2005), 288–295.
44. Patti, G.J., Yanes, O., Siuzdak, G., Innovation: metabolomics: the apogee of the omics trilogy. Nat. Rev. Mol. Cell Biol. 13 (2012), 263–269.
45. Poldrack, R.A., Laumann, T.O., Koyejo, O., Gregory, B., Hover, A., Chen, M.Y., Gorgolewski, K.J., Luci, J., Joo, S.J., Boyd, R.L., Hunicke-Smith, S., Simpson, Z.B., Caven, T., Sochat, V., Shine, J.M., Gordon, E., Snyder, A.Z., Adeyemo, B., Petersen, S.E., Glahn, D.C., Reese Mckay, D., Curran, J.E., Goring, H.H., Carless, M.A., Blangero, J., Dougherty, R., Leemans, A., Handwerker, D.A., Frick, L., Marcotte, E.M., Mumford, J.A., Long-term neural and physiological phenotyping of a single human. Nat. Commun., 6, 2015, 8885.
46. Ramautar, R., Berger, R., van der Greef, J., Hankemeier, T., Human metabolomics: strategies to understand biology. Curr. Opin. Chem. Biol. 17 (2013), 841–846.
47. Rasmussen, M.A., Colding-Jorgensen, M., Hansen, L.T., Bro, R., Multivariate evaluation of pharmacological responses in early clinical trials - a study of rIL-21 in the treatment of patients with metastatic melanoma. Br. J. Clin. Pharmacol. 69 (2010), 379–390.
48. Salomaa, V., Genetic and environmental contributions to cardiovascular risk: lessons from North Karelia and FINRISK. Glob. Heart 11 (2016), 229–233.
49. Scalbert, A., Brennan, L., Manach, C., Andres-Lacueva, C., Dragsted, L.O., Draper, J., Rappaport, S.M., van der Hooft, J.J., Wishart, D.S., The food metabolome: a window over dietary exposure. Am. J. Clin. Nutr. 99 (2014), 1286–1308.
50. Schmidt, S., Post, T.M., Boroujerdi, M.A., van Kesteren, C., Ploeger, B.A., Della Pasqua, O.E., Danhof, M., 2010. Disease Progression Analysis: Towards Mechanism-Based Models, in: Kimko, H.H.C., Peck, C.C. (Eds.), Clinical Trial Simulations: Applications and Trends. Springer New York, pp. 433–455.
51. Sengupta, A., Krishnaiah, S.Y., Rhoades, S., Growe, J., Slaff, B., Venkataraman, A., Olarerin-George, A.O., Van Dang, C., Hogenesch, J.B., Weljie, A.M., Deciphering the duality of clock and growth metabolism in a cell autonomous system using NMR profiling of the Secretome. Metabolites, 6, 2016.
52. Sumner, L.W., Amberg, A., Barrett, D., Beale, M.H., Beger, R., Daykin, C.A., Fan, T.W., Fiehn, O., Goodacre, R., Griffin, J.L., Hankemeier, T., Hardy, N., Harnly, J., Higashi, R., Kopka, J., Lane, A.N., Lindon, J.C., Marriott, P., Nicholls, A.W., Reily, M.D., Thaden, J.J., Viant, M.R., Proposed minimum reporting standards for chemical analysis chemical analysis Working group (CAWG) metabolomics standards initiative (MSI). Metabolomics 3 (2007), 211–221.
53. Valitalo, P.A., Griffioen, K., Rizk, M.L., Visser, S.A., Danhof, M., Rao, G., van der Graaf, P.H., van Hasselt, J.G., Structure-based prediction of anti-infective drug concentrations in the human lung epithelial lining fluid. Pharm. Res. 33 (2016), 856–867.
54. Van Hasselt, J.G., Van Calsteren, K., Heyns, L., Han, S., Mhallem Gziri, M., Schellens, J.H., Beijnen, J.H., Huitema, A.D., Amant, F., Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel. Ann. Oncol. 25 (2014), 2059–2065.
55. Van Hasselt, J.G., van Eijkelenburg, N.K., Beijnen, J.H., Schellens, J.H., Huitema, A.D., Design of a drug-drug interaction study of vincristine with azole antifungals in pediatric cancer patients using clinical trial simulation. Pediatr. Blood Cancer 61 (2014), 2223–2229.
56. Vigor, C., Bertrand-Michel, J., Pinot, E., Oger, C., Vercauteren, J., Le Faouder, P., Galano, J.M., Lee, J.C., Durand, T., Non-enzymatic lipid oxidation products in biological systems: assessment of the metabolites from polyunsaturated fatty acids. J Chromatogr B Analyt Technol Biomed Life Sci 964 (2014), 65–78.
57. Wallace, M., Hashim, Y.Z., Wingfield, M., Culliton, M., McAuliffe, F., Gibney, M.J., Brennan, L., Effects of menstrual cycle phase on metabolomic profiles in premenopausal women. Hum. Reprod. 25 (2010), 949–956.
58. Want, E.J., Wilson, I.D., Gika, H., Theodoridis, G., Plumb, R.S., Shockcor, J., Holmes, E., Nicholson, J.K., Global metabolic profiling procedures for urine using UPLC-MS. Nat. Protoc. 5 (2010), 1005–1018.
59. Wishart, D.S., Emerging applications of metabolomics in drug discovery and precision medicine. Nat. Rev. Drug Discov. 15 (2016), 473–484.
60. Yazdani, A., Yazdani, A., Samiei, A., Boerwinkle, E., Identification, analysis, and interpretation of a human serum metabolomics causal network in an observational study. J. Biomed. Inform. 63 (2016), 337–343.